Skip to main content

Advertisement

SpringerLink
Log in

siRNA-Mediated Silencing of HMGA2 Induces Apoptosis and Cell Cycle Arrest in Human Colorectal Carcinoma

  • Original Research
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

Purpose

Overexpression of HMGA2, known as small non-histone chromosomal protein, is associated with progression of various tumors, including colorectal cancers. The aim of this study was to investigate the effect of a specific HMGA2 siRNA on apoptosis and cell cycle of HCT-116 (colorectal carcinoma) cells.

Methods

The cells were transfected with siRNAs using a transfection reagent. The cytotoxic effects of HMGA2 siRNA on colorectal carcinoma cells were determined using MTT assay. Relative HMGA2 mRNA and protein levels were measured by QRT-PCR and western blotting, respectively. Apoptosis was measured by a TUNEL test based on labeling of DNA strand breaks. We also evaluated caspase-3, caspase-8, and caspase-9 expression by QRTPCR to determine which pathway is involved in apoptosis. Cell cycle was assessed by FACS and cell cycle analysis using PI DNA staining.

Results

HMGA2 siRNA significantly reduced both mRNA and protein expression levels 48 h after transfection and dose-dependent manner in colorectal carcinoma cells. We also showed that the silencing of HMGA2 led to the induction of apoptosis through intrinsic pathway and cell cycle arrest in G2/M phases of interphase in HCT-116 cells in vitro.

Conclusions

These results propose that HMGA2 might play an important role in the progression of colorectal carcinoma and might be a potential therapeutic target for trigger apoptosis and cell cycle arrest in colorectal carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.

    Article  PubMed  Google Scholar 

  2. Lotfipour F, Hallaj-Nezhadi S, Valizadeh H, Dastmalchi S, Baradaran B, Jalali MB, Dobakhti F. Preparation of chitosan-plasmid DNA nanoparticles encoding interleukin-12 and their expression in CT-26 colon carcinoma cells. Journal of Pharmacy & Pharmaceutical Sciences. 2011;14(2):181–95.

    Article  Google Scholar 

  3. Mohammadi A, Mansoori B, Aghapour M, Baradaran PC, Shajari N, Davudian S, Salehi S, Baradaran B. The herbal medicine Utrica dioica inhibits proliferation of colorectal cancer cell line by inducing apoptosis and arrest at the G2/M phase. Journal of Gastrointestinal Cancer. 2016:1–9.

  4. Valiyari S, Jahanban-Esfahlan R, Shahneh FZ, Yaripour S, Baradaran B, Delazar A. Cytotoxic and apoptotic activity of Scrophularia oxysepala in MCF-7 human breast cancer cells. Toxicol Environ Chem. 2013;95(7):1208–20.

    Article  CAS  Google Scholar 

  5. Luwor R, Baradaran B, Taylor L, Iaria J, Nheu T, Amiry N, Hovens C, Wang B, Kaye A, Zhu H. Targeting Stat3 and Smad7 to restore TGF-β cytostatic regulation of tumor cells in vitro and in vivo. Oncogene. 2013;32(19):2433–41.

    Article  CAS  PubMed  Google Scholar 

  6. Matzke M, Matzke AJ. RNAi extends its reach. Science. 2003;301(5636):1060–1.

    Article  CAS  PubMed  Google Scholar 

  7. Natarajan S, Hombach-Klonisch S, Dröge P, Klonisch T. HMGA2 inhibits apoptosis through interaction with ATR-CHK1 signaling complex in human cancer cells. Neoplasia. 2013;15(3):263–IN213.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Cleynen I, Van de Ven WJ. The HMGA proteins: a myriad of functions (Review). Int J Oncol. 2008;32(2):289–305.

    CAS  PubMed  Google Scholar 

  9. Tessari MA, Gostissa M, Altamura S, Sgarra R, Rustighi A, Salvagno C, Caretti G, Imbriano C, Mantovani R, Del Sal G. Transcriptional activation of the cyclin A gene by the architectural transcription factor HMGA2. Mol Cell Biol. 2003;23(24):9104–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. De Martino I, Visone R, Wierinckx A, Palmieri D, Ferraro A, Cappabianca P, Chiappetta G, Forzati F, Lombardi G, Colao A. HMGA proteins up-regulate CCNB2 gene in mouse and human pituitary adenomas. Cancer Res. 2009;69(5):1844–50.

    Article  CAS  PubMed  Google Scholar 

  11. Manfioletti G, Giancotti V, Bandiera A, Buratti E, Sautièere P, Cary P, Crane-Robinson C, Coles B, Goodwin G. cDNA cloning of the HML-C phosphoprotein, a nclear protein associated with neoplastic and undifferentiated phenotypes. Nucleic Acids Res. 1991;19(24):6793–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Zhou X, Benson KF, Ashar HR, Chada K (1995) Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C.

  13. Rogalla P, Drechsler K, Frey G, Hennig Y, Helmke B, Bonk U, Bullerdiek J. HMGI-C expression patterns in human tissues. Implications for the genesis of frequent mesenchymal tumors. Am J Pathol. 1996;149(3):775.

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Guang-meng X, Hai-na Z, Xiao-feng T, Mei S, Xue-dong F. Effect of HMGA2 shRNA on the cell proliferation and invasion of human colorectal cancer SW480 cells in vitro. CHEMICAL RESEARCH IN CHINESE UNIVERSITES. 2012;28(2):264–8.

    Google Scholar 

  15. Belge G, Meyer A, Klemke M, Burchardt K, Stern C, Wosniok W, Loeschke S, Bullerdiek J. Upregulation of HMGA2 in thyroid carcinomas: a novel molecular marker to distinguish between benign and malignant follicular neoplasias. Genes Chromosom Cancer. 2008;47(1):56–63.

    Article  CAS  PubMed  Google Scholar 

  16. Rogalla P, Drechsler K, Kazmierczak B, Rippe V, Bonk U, Bullerdiek J. Expression of HMGI-C, a member of the high mobility group protein family, in a subset of breast cancers: relationship to histologic grade. Mol Carcinog. 1997;19(3):153–6.

    Article  CAS  PubMed  Google Scholar 

  17. Langelotz C, Schmid P, Jakob C, Heider U, Wernecke K, Possinger K, Sezer O. Expression of high-mobility-group-protein HMGI-C mRNA in the peripheral blood is an independent poor prognostic indicator for survival in metastatic breast cancer. Br J Cancer. 2003;88(9):1406–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Di Cello F, Hillion J, Hristov A, Wood LJ, Mukherjee M, Schuldenfrei A, Kowalski J, Bhattacharya R, Ashfaq R, Resar LM. HMGA2 participates in transformation in human lung cancer. Mol Cancer Res. 2008;6(5):743–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Abe N, Watanabe T, Suzuki Y, Matsumoto N, Masaki T, Mori T, Sugiyama M, Chiappetta G, Fusco A, Atomi Y. An increased high-mobility group A2 expression level is associated with malignant phenotype in pancreatic exocrine tissue. Br J Cancer. 2003;89(11):2104–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Hristov AC, Cope L, Reyes MD, Singh M, Iacobuzio-Donahue C, Maitra A, Resar L. HMGA2 protein expression correlates with lymph node metastasis and increased tumor grade in pancreatic ductal adenocarcinoma. Mod Pathol. 2009;22(1):43–9.

    Article  CAS  PubMed  Google Scholar 

  21. Miyazawa J, Mitoro A, Kawashiri S, Chada KK, Imai K. Expression of mesenchyme-specific gene HMGA2 in squamous cell carcinomas of the oral cavity. Cancer Res. 2004;64(6):2024–9.

    Article  CAS  PubMed  Google Scholar 

  22. Malek A, Bakhidze E, Noske A, Sers C, Aigner A, Schäfer R, Tchernitsa O. HMGA2 gene is a promising target for ovarian cancer silencing therapy. Int J Cancer. 2008;123(2):348–56.

    Article  CAS  PubMed  Google Scholar 

  23. Park S-M, Shell S, Radjabi AR, Schickel R, Feig C, Boyerinas B, Dinulescu DM, Lengyel E, Peter ME. Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. Cell Cycle. 2007;6(21):2585–90.

    Article  CAS  PubMed  Google Scholar 

  24. Yang G, Zhang L, Bo J, Hou K, Cai X, Chen Y, Li H, Liu D, Huang Y. Overexpression of HMGA2 in bladder cancer and its association with clinicopathologic features and prognosis: HMGA2 as a prognostic marker of bladder cancer. European Journal of Surgical Oncology (EJSO). 2011;37(3):265–71.

    Article  CAS  Google Scholar 

  25. Motoyama K, Inoue H, Nakamura Y, Uetake H, Sugihara K, Mori M. Clinical significance of high mobility group A2 in human gastric cancer and its relationship to let-7 microRNA family. Clin Cancer Res. 2008;14(8):2334–40.

    Article  CAS  PubMed  Google Scholar 

  26. Huang M-L, Chen C-C, Chang L-C. Gene expressions of HMGI-C and HMGI (Y) are associated with stage and metastasis in colorectal cancer. Int J Color Dis. 2009;24(11):1281–6.

    Article  Google Scholar 

  27. Wang X, Liu X, Li AY-J, Chen L, Lai L, Lin HH, Hu S, Yao L, Peng J, Loera S. Overexpression of HMGA2 promotes metastasis and impacts survival of colorectal cancers. Clin Cancer Res. 2011;17(8):2570–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Mansoori B, Mohammadi A, Goldar S, Shanehbandi D, Mohammadnejad L, Baghbani E, Kazemi T, Kachalaki S, Baradaran B (2016) Silencing of high mobility group isoform IC (HMGI-C) enhances paclitaxel chemosensitivity in breast adenocarcinoma cells (MDA-MB-468).

  29. Karami H, Baradaran B, Esfahani A, Estiar MA, Naghavi-Behzad M, Sakhinia M, Sakhinia E. siRNA-Mediated silencing of survivin inhibits proliferation and enhances etoposidechemosensitivity in acute myeloid leukemia cells. Asian Pac J Cancer Prev. 2013;14(12):7719–24.

    Article  PubMed  Google Scholar 

  30. Zheng TS, Hunot S, Kuida K, Momoi T, Srinivasan A, Nicholson DW, Lazebnik Y, Flavell RA. Deficiency in caspase-9 or caspase-3 induces compensatory caspase activation. Nat Med. 2000;6(11):1241–7.

    Article  CAS  PubMed  Google Scholar 

  31. Mansoori B, Mohammadi A, Shirjang S, Baradaran B (2016) HMGI-C suppressing induces P53/caspase9 axis to regulate apoptosis in breast adenocarcinoma cells. Cell Cycle (just-accepted):00–00

  32. Cuddihy AR, O’Connell MJ. Cell-cycle responses to DNA damage in G2. Int Rev Cytol. 2003;222:99–140.

    Article  PubMed  Google Scholar 

  33. Chiappetta G, Ferraro A, Vuttariello E, Monaco M, Galdiero F, De Simone V, Califano D, Pallante P, Botti G, Pezzullo L. HMGA2 mRNA expression correlates with the malignant phenotype in human thyroid neoplasias. Eur J Cancer. 2008;44(7):1015–21.

    Article  CAS  PubMed  Google Scholar 

  34. Gattas GJ, Quade BJ, Nowak RA, Morton CC. HMGIC expression in human adult and fetal tissues and in uterine leiomyomata. Genes Chromosom Cancer. 1999;25(4):316–22.

    Article  CAS  PubMed  Google Scholar 

  35. Hebert C, Norris K, Scheper MA, Nikitakis N, Sauk JJ. High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. Mol Cancer. 2007;6(1).

  36. Mahajan A, Liu Z, Gellert L, Zou X, Yang G, Lee P, Yang X, Wei J-J. HMGA2: a biomarker significantly overexpressed in high-grade ovarian serous carcinoma. Mod Pathol. 2010;23(5):673–81.

    Article  CAS  PubMed  Google Scholar 

  37. Meyer B, Loeschke S, Schultze A, Weigel T, Sandkamp M, Goldmann T, Vollmer E, Bullerdiek J. HMGA2 overexpression in non-small cell lung cancer. Mol Carcinog. 2007;46(7):503–11.

    Article  CAS  PubMed  Google Scholar 

  38. Wu J, Liu Z, Shao C, Gong Y, Hernando E, Lee P, Narita M, Muller W, Liu J, Wei J-J. HMGA2 overexpression-induced ovarian surface epithelial transformation is mediated through regulation of EMT genes. Cancer Res. 2011;71(2):349–59.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Montazami N, Kheirandish M, Majidi J, Yousefi M, Yousefi B, Mohamadnejad L, Shanebandi D, Estiar M, Khaze V, Mansoori B. siRNA-mediated silencing of MDR1 reverses the resistance to oxaliplatin in SW480/OxR colon cancer cells. Cellular and molecular biology (Noisy-le-Grand, France). 2015;61(2):98.

    CAS  Google Scholar 

  40. Devi G. siRNA-based approaches in cancer therapy. Cancer Gene Ther. 2006;13(9):819–29.

    Article  CAS  PubMed  Google Scholar 

  41. Yang M, Mattes J. Discovery, biology and therapeutic potential of RNA interference, microRNA and antagomirs. Pharmacol Ther. 2008;117(1):94–104.

    Article  CAS  PubMed  Google Scholar 

  42. Shan G. RNA interference as a gene knockdown technique. Int J Biochem Cell Biol. 2010;42(8):1243–51.

    Article  CAS  PubMed  Google Scholar 

  43. Kachalaki S, Baradaran B, Majidi J, Yousefi M, Shanehbandi D, Mohammadinejad S, Mansoori B. Reversal of chemoresistance with small interference RNA (siRNA) in etoposide resistant acute myeloid leukemia cells (HL-60). Biomedicine & Pharmacotherapy. 2015;75:100–4.

    Article  CAS  Google Scholar 

  44. Mansoori B, Shotorbani SS, Baradaran B. RNA interference and its role in cancer therapy. Advanced pharmaceutical bulletin. 2014;4(4).

  45. Mansoori B, Mohammadi A, Shir Jang S, Baradaran B. Mechanisms of immune system activation in mammalians by small interfering RNA (siRNA. Artificial cells, nanomedicine, and biotechnology. 2015:1–8.

  46. Musavi Shenas SMH, Mansoori B, Mohammadi A, Salehi S, Kaffash B, Talebi B, Babaloo Z, Shanehbandi D, Baradaran B. SiRNA-mediated silencing of snail-1 induces apoptosis and alters micro RNA expression in human urinary bladder cancer cell line. Artif Cells Nanomed Biotechnol. 2016:1–6.

  47. Brantl S. Antisense-RNA regulation and RNA interference. Biochimica et Biophysica Acta (BBA)-Gene Structure and Expression. 2002;1575(1):15–25.

    Article  CAS  Google Scholar 

  48. Aoki Y, Cioca D, Oidaira H, Kamiya J, Kiyosawa K. RNA interference may be more potent than antisense RNA in human cancer cell lines. Clin Exp Pharmacol Physiol. 2003;30(1–2):96–102.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

    Sahar Esmailzadeh, Behzad Mansoori, Ali Mohammadi, Dariush Shanehbandi & Behzad Baradaran

  2. Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran

    Behzad Mansoori

Authors
  1. Sahar Esmailzadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Behzad Mansoori
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ali Mohammadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dariush Shanehbandi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Behzad Baradaran
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Behzad Baradaran.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Esmailzadeh, S., Mansoori, B., Mohammadi, A. et al. siRNA-Mediated Silencing of HMGA2 Induces Apoptosis and Cell Cycle Arrest in Human Colorectal Carcinoma. J Gastrointest Canc 48, 156–163 (2017). https://doi.org/10.1007/s12029-016-9871-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-016-9871-z

Keywords

Search

Navigation